It is the policy of the AAFP that all individuals in a position to control content disclose relationships with commercial entities upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest and, if identified, are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in this CME activity.
The following individuals in a position to control content for this activity have disclosed the following relevant financial relationships:
- EJ Mayeaux, Jr., MD, FAAFP, Consultant or Advisory Board with Merck Vaccine on the topic HPV and Pharmaderm on the topic EGWs.
- Edward J. Shahady, MD, FAAFP, has disclosed: Diabetes Advisory board for Janssen; Novo; and Sanofi. Novo – Diabetes topics. Merck – Group Visits.
All other individuals in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.
Faculty members shall disclose when an unapproved or investigational use of a product not yet approved for any purpose is discussed during an educational activity. Faculty members shall disclose that the product is not labeled for the use under discussion or that the product is still investigational. It is not the purpose of this policy to prohibit or limit the exchange of views in scientific and educational discussions, but to ensure that faculty members disclose to participants that such discussion will take place.
The following faculty members have returned forms declaring that the content of their presentations at this AAFP-sponsored educational activity will include discussion of unapproved or investigational uses of products or devices, as indicated:
- EJ Mayeaux, Jr., MD, FAAFP will include discussion of the use of 0.5% Podophyllotoxin, Phenol, 10% KOH, Cantharidin, and Imiquimod for Molluscum Contagiosum. He will also include discussion of the use of 5-FU, Tretinoin, and Imiquimod for flat warts.
All other faculty members for this activity have indicated the content of their presentations for this AAFP-produced educational activity will not include discussion of unapproved or investigational uses of products or devices.
The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.
The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person.
Every effort has been made to ensure the accuracy of the data presented here. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application.
This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
Materials/Contents are not to be reproduced, published or distributed, in whole or in part, in any form or medium, without the express written permission of the American Academy of Family Physicians.